Department of Pharmacy Practice, Faculty of Pharmacy and Health Sciences, University of Balochistan, Quetta, Pakistan.
Department of Biology, Syed Babar Ali School of Science and Engineering, Lahore University of Management Sciences, Lahore, Pakistan.
BMC Infect Dis. 2021 Dec 4;21(1):1209. doi: 10.1186/s12879-021-06935-6.
There was a complete lack of information about the treatment outcomes of rifampicin/multidrug resistant (RR/MDR) childhood TB patients (age ≤ 14 years) from Pakistan, an MDR-TB 5th high burden country. Therefore, this study evaluated the socio-demographic characteristics, drug resistance pattern, treatment outcomes and factors associated with unsuccessful outcomes among childhood RR/MDR-TB patients in Pakistan.
This was a multicentre retrospective record review of all microbiologically confirmed childhood RR/MDR-TB patients (age ≤ 14 years) enrolled for treatment at seven units of programmatic management of drug-resistant TB (PMDT) in Pakistan. The baseline and follow-up information of enrolled participants from treatment initiation until the end of treatment were retrieved from electronic nominal recording and reporting system. World Health Organization (WHO) defined criterion was used for deciding treatment outcomes. The outcomes of "cured" and "treatment completed" were collectively grouped as successful, whereas "death", "treatment failure" and "lost to follow-up" were grouped together as unsuccessful outcomes. Multivariable binary logistic regression analysis was used to find factors associated with unsuccessful outcomes. A p-value < 0.05 reflected statistically significant findings.
A total of 213 children RR/MDR-TB (84 RR and 129 MDR-TB) were included in the study. Majority of them were females (74%), belonged to the age group 10-14 years (82.2%) and suffered from pulmonary TB (85.9%). A notable proportion (37.1%) of patients had no history of previous TB treatment. Patients were resistant to a median of two drugs (interquartile range: 1-4) and 23% were resistant to any second line anti-TB drug. A total of 174 (81.7%) patients achieved successful treatment outcomes with 144 (67.6%) patients being cured and 30 (14.1%) declared treatment completed. Among the 39 (18.3%) patients with unsuccessful outcomes, 35 (16.4%) died and 4 (1.9%) experienced treatment failure. In multivariable analysis, the use of ethambutol had statistically significant negative association with unsuccessful outcomes (odds ratio = 0.36, p-value = 0.02).
In this study, the WHO target of successful treatment outcomes (≥ 75%) among childhood RR/MDR-TB patients was achieved. The notable proportion of patients with no history of previous TB treatment (37.1%) and the disproportionately high number of female patients (74%) respectively stress for infection control measures and provision of early and high quality care for female drug susceptible TB patients.
来自第五大耐多药结核高负担国家巴基斯坦的儿童利福平/耐多药(RR/MDR)结核病患者(年龄≤14 岁)的治疗结果信息完全缺失。因此,本研究评估了巴基斯坦七个规划管理耐药结核病(PMDT)单位中接受治疗的所有经微生物学证实的儿童 RR/MDR-TB 患者(年龄≤14 岁)的社会人口学特征、耐药模式、治疗结果以及与治疗失败相关的因素。
这是一项对所有接受治疗的儿童 RR/MDR-TB 患者(年龄≤14 岁)的回顾性多中心记录回顾,这些患者均在巴基斯坦七个规划管理耐药结核病(PMDT)单位接受治疗。从电子病历记录和报告系统中检索了纳入参与者从治疗开始到治疗结束的基线和随访信息。采用世界卫生组织(WHO)的标准来判断治疗结果。“治愈”和“治疗完成”的结果被归为成功,而“死亡”、“治疗失败”和“失访”则归为不成功的结果。采用多变量二项逻辑回归分析发现与治疗失败相关的因素。p 值<0.05 表示具有统计学意义的发现。
共有 213 名儿童 RR/MDR-TB(84 名 RR 和 129 名 MDR-TB)纳入本研究。其中大多数为女性(74%),年龄在 10-14 岁(82.2%),患有肺结核(85.9%)。相当一部分(37.1%)患者既往无结核病治疗史。患者耐药中位数为两种药物(四分位间距:1-4),23%对任何二线抗结核药物耐药。174 名(81.7%)患者获得了成功的治疗结果,其中 144 名(67.6%)患者治愈,30 名(14.1%)患者完成治疗。在 39 名(18.3%)治疗失败的患者中,35 名(16.4%)死亡,4 名(1.9%)治疗失败。多变量分析显示,使用乙胺丁醇与治疗失败呈统计学显著负相关(比值比=0.36,p 值=0.02)。
在这项研究中,儿童 RR/MDR-TB 患者的世卫组织治疗成功目标(≥75%)得到了实现。既往无结核病治疗史的患者比例较高(37.1%),女性患者比例过高(74%),这分别强调了感染控制措施和为女性药物敏感结核病患者提供早期和高质量护理的重要性。